Wockhardt LimitedNSE: WOCKPHARMA

Press Release Oct 11 2024

· Issued by Wockhardt Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Wockhardt Limited has submitted a press release regarding its novel antibiotic Miqnaf, which has received a favorable recommendation from the Subject Expert Committee of the Central Drugs Standard Control Organization for treating Community-Acquired Bacterial Pneumonia. Miqnaf is noted for being the first-ever once-a-day treatment for CABP, particularly effective against multi-drug resistant pathogens. This development is expected to provide a reliable treatment option and reduce hospitalization needs for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Wockhardt Limited has informed the Exchange regarding a press release dated October 11, 2024, titled "Wockhardt s yet another novel antibiotic MiqnafTM (Nafithromycin) receives favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community-Acquired Bacterial Pneumonia (CABP).".

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases